Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | DRD1 | P21728 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enprazepine SCHEMBL31438605 | 1.00 | HRH1 (0.51) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| Prazepine SCHEMBL2109939 | 0.78 | HRH1 (0.55) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| SCHEMBL8951821 | 0.75 | SLC6A4 (0.51) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| SCHEMBL15868114 | 0.74 | HRH1 (0.53) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| SCHEMBL28863147 | 0.72 | MAPT (0.82) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| SCHEMBL5449154 | 0.72 | ALDH1A1 (0.50) | LMNACYP2D6HTR1ADRD2ALDH1A1 | |
| SCHEMBL11474941 | 0.71 | SLC6A4 (0.50) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| Hydrochloric Acid SCHEMBL11475198 | 0.70 | LMNA (0.51) | HRH1SLC6A4LMNAMAPTCYP2D6 | |
| SCHEMBL4405132 | 0.69 | KDM4E (0.59) | HRH1SLC6A4LMNAMAPTHTR1A | |
| Imipramine SCHEMBL17004048 | 0.68 | SLC6A4 (1.00) | HRH1SLC6A4LMNAMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | claimed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2013126205-A1 | MIXED MONOAMINE REUPTAKE INHIBITOR IN A BIODEGRADABLE POLYMER CARRIER | WARSAW ORTHOPEDIC, INC. (US) | 2013-08-29 | — | — | WO | claimed |
| US-20130217673-A1 | MIXED MONOAMINE REUPTAKE INHIBITOR IN A BIODEGRADABLE POLYMER CARRIER | WARSAW ORTHOPEDIC, INC (US) | 2013-08-22 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | disclosed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | HRH1 2197/4885SLC6A4 2995/4885LMNA 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.